Two experts address the impact of disease course on therapy, general instructions for patients, individualizing treatment, thymectomy, newer selective immunotherapies and more.
Two experts address the clinical hallmarks of this chronic autoimmune neuromuscular disorder as well as risk factors and the role of antibody testing and electrodiagnostic tests.
For the 5% to 20% of patients with generalized myasthenia gravis who have suboptimal response to pyridostigmine or substantial adverse effects, it may be time to consider immunosuppressive therapy. This short review offers guidance on choice of agents.
Progress in our ability to diagnose and treat this autoimmune disorder has been encouraging — and all signs suggest that it will continue.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Dr. Robert Bermel reflects on some presentations at the recent AAN meeting that could make 2018 a very consequential year in neurology.